La chaîne d'options affiche les données clés des options sur actions de Allogene Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Allogene Therapeutics..

Allogene Therapeutics (NASDAQ:ALLO) Stock, Chaîne d'Options

ALLOGENE THERAPEUTICS INC

Allogene Therapeutics

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics Inc

ALLON THERAPEUTICS INC by Allon Therapeutics Inc.

ALLOVIR INC

Allot Ltd

News

Press Releases

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Earnings

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

Health Care

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Small Cap

Opinion

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

ALLO

CATX

ONCY

TSX:ONC

VSTM

AC Immune

Alector

Annexon

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Editas Medicine

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genfit

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Jade Biosciences

Lexeo Therapeutics

Lyell Immunopharma

Monopar Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Puma Biotechnology

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Entrada Therapeutics, Inc. - Common Stock

Comments

Allogene Therapeutics

Allogene Therapeutics (ALLO) Options

Allogene Therapeutics (NASDAQ:ALLO) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL